Page 1,904«..1020..1,9031,9041,9051,906..1,9101,920..»

Japanese scientist Obokata fails to recreate 'provocative' STAP stem cells and resigns

Posted: December 19, 2014 at 1:57 pm

A Japanese scientist once hailed a hero resigned Friday (19.12.2014) after acknowledging she could not reproduce the results of her groundbreaking "STAP" stem cell research in a government lab under video camera surveillance.

Haruko Obokata's highly publicized fall from grace led to critiques against the international science journal which published her research, to reforms at the Riken Center for Developmental Biology (CDB) in Kobe, and contributed to the suicide of co-author and respected stem cell scientist, Yoshiki Sasai.

"Now, I am just exhausted. For the results to end this way is just perplexing," Obokata said in her statement Friday. The researcher, who added she could not find the words for an apology, had refused media appearances since April.

Two science papers written by Obokata and Sasai were published in the international science journal "Nature" in January. The researchers claimed they could create stem cells out of blood cells - albeit in mice - through the use of an acid solution. They called the process Stimulus-Triggered Acquisition of Pluripotency (STAP).

The STAP process would have greatly simplified the creation of stem cells from other cells.

Researchers believe stem cells will one day be used to treat a range of diseases, from Parkinson's Disease to blindness, since they can regenerate or repair damaged tissues in the human body.

Yoshiki Sasai was 52

However, scientists quickly discovered mistakes and contradictions in the STAP papers' data and picture captions, and labs around the world were never able to replicate their findings.

In June, Obakata retracted the papers.

In August, co-author Sasai hanged himself.

Read more:
Japanese scientist Obokata fails to recreate 'provocative' STAP stem cells and resigns

Posted in Stem Cells | Comments Off on Japanese scientist Obokata fails to recreate 'provocative' STAP stem cells and resigns

Stem cells and cell adaptations to particular functions

Posted: December 19, 2014 at 7:02 am

Posted in Virginia Stem Cells | Comments Off on Stem cells and cell adaptations to particular functions

Mutations Need Help From Evolution to Cause Cancer

Posted: December 19, 2014 at 6:53 am

Contact Information

Available for logged-in reporters only

Newswise Why are older people at higher risk for developing cancer? Prevailing opinion holds that, over time, your bodys cells accumulate DNA damage and that eventually this damage catches up with the body in a way that causes cancer. A University of Colorado Cancer Center study published today in the journal Aging shows that this prevailing opinion is incomplete. In addition to DNA damage, cancer depends on the slow degradation of tissue that surrounds cancer cells, something that naturally comes with aging.

Its really all about natural selection and survival of the fittest, says James DeGregori, PhD, investigator at the CU Cancer Center, professor of Biochemistry and Molecular Genetics at the CU School of Medicine, and the papers senior author.

When youre young, healthy cells are optimized to the surrounding tissue theyre the fittest, DeGregori says. At that point, any mutation that affects function makes a cell less fit, so cells with mutations, even cancer-causing mutations, are out-competed by the young, fit, healthy cells. But when the tissue landscape changes with aging, healthy cells may no longer be optimized to their surroundings. In this aged landscape, mutations may actually make certain cells better, allowing them to out-compete the normal cells and form tumors. Thats why older people get cancer.

Working in the DeGregori Lab, postdoc and first author Andrii Rozhok, PhD, created mathematical models of just this kind of natural selection in hematopoietic or blood cells. Like predicting the weather, Rozhok combined several variables into a model and then asked how well the model could predict what we see in the real world. For example, in the case of weather, accurately taking into account barometric pressure and the calendar day could predict a snowstorm. Similarly, if you were to believe prevailing opinion, youd say that mutation accumulation would predict leukemia development. When Rozhok plugged only mutation variables into his model, however, there was poor fit. That is to say, the model could not accurately predict stem cell changes over time or leukemia development.

We knew mutations would play a role, perhaps even a big role, but it became clear there was something else going on. We had been looking inside cells for the causes of cancer, but that wasnt enough. There was something happening outside the cells that mattered, and that something is what allows cancer to form, DeGregori says.

Rozhok and colleagues then added more variables to the model to account for microenvironmental tissue decline. Suddenly, there was a much better fit. The new model, driven by age-related changes in stem cell fitness and behavior, accurately predicts the point at which a cancer cell might out-compete the normal cells and become a leukemia. Importantly, the model demonstrates that the systemic processes accompanying general tissue decline with age have a crucial power in governing cancer cell fates and the odds of developing cancer.

Wed always thought the tissue landscape was important, but we didnt know how important, DeGregori says. He points out that natural selection only cares about the human body until it passes reproductive age. We have programmed maintenance that takes care of our bodies and keeps us fit until around age 40. At that point, our maintenance program gets lazy. Our tissue landscape starts to change, and unfortunately it changes in ways that allow cancer cells to out-compete normal cells.

In all, We show that mutations, although necessary, cannot promote blood cancer development without an age-altered tissue microenvironment, the researchers write.

Here is the original post:
Mutations Need Help From Evolution to Cause Cancer

Posted in Colorado Stem Cells | Comments Off on Mutations Need Help From Evolution to Cause Cancer

Europe boosts stem cell patent rights

Posted: December 19, 2014 at 6:43 am

Cultures of ISCOs parthenogenetic stem cells, made from unfertilized human egg cells.

Stem cells produced by Carlsbad's International Stem Cell Corp. can be patented, a European court ruled Thursday. The decision allows the biotech company to get patents for its stem cells made from unfertilized, or parthenogenetic, human egg cells.

In related news, the company said Thursday it plans to apply by the end of the year to do a clinical trial of a Parkinson's treatment derived from its parthenogenetic cells.

The trial should begin in a couple of months, said Simon Craw, the company's executive vice president of business development. The company will need to raise about $5 million for the trial, he said.

International Stem Cell is developing these cells as an alternative to human embryonic stem cells, which many regard as morally wrong. Moreover, the parthenogenetic cells have a reduced tendency to cause immune reactions when transplanted, which could make them an attractive use for therapy.

The European Union forbids patents on the use of human embryos, the source of embryonic stem cells. Patent applications in the United Kingdom and other countries for parthenogenetic cells have been held up because dividing parthenogenetic cells resemble embryos.

However, the Court of Justice of the European Union in Luxembourg ruled that parthenogenetic cells are not embryos, so cells made from them are eligible for patenting. While the structures look like embryos, they stop growing in a few days and die.

"In todays judgment, the Court holds that, in order to be classified as a human embryo, a non-fertilised human ovum must necessarily have the inherent capacity of developing into a human being," the European court said in a press release. "Consequently, the mere fact that a parthenogenetically-activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo."

Shares of the company closed after the decision at 8 cents, up 1 cent for the day.

The decision is a great turning point in the legal struggle to patent parthenogenetic stem cells in Europe, Craw said.

Read more:
Europe boosts stem cell patent rights

Posted in Stem Cell Therapy | Comments Off on Europe boosts stem cell patent rights

Okyanos Expands World-Class Cell Therapy Medical Team

Posted: December 19, 2014 at 6:43 am

Freeport, Grand Bahama (PRWEB) December 18, 2014

Okyanos, the leader in cell therapy, announced the expansion of its medical team to accommodate the growing demand for cell therapy to treat patients with chronic unmet needs for which adult stem cell therapy using cells from a persons own fat (adipose) tissue has been found to be safe and efficacious. Led by a prestigious team of U.S.-licensed physicians and nursing staff, the team includes Dr. Todd Malan, Chief Cell Therapy Officer and pioneer of adipose-derived stem cell therapy, and is joined by Dr. Matthew Mick, Cardiologist, FACC, Fellowship at Cleveland Clinic.

We are very pleased to have such a competent and highly regarded aggregate of expertise, said Okyanos CEO Matt Feshbach. Our team is comprised of leaders in their respective fields, each of whom is committed to bringing about a new standard of care and better quality of life to our patients.

Todd Malan, MD, serves as the Chief Cell Therapy Officer and General Surgeon at Okyanos, overseeing the fat-harvesting and stem cell isolation step of the Okyanos cell therapy process. A pioneer of fat-derived stem cell therapies, he became the first physician in the U.S. to utilize stem cells from fat for soft tissue reconstruction in October 2009, combining water-assisted fat-harvesting, fat transfer and adult stem cell technologies.

Matthew J. Mick, MD, is a triple board-certified interventional cardiologist. After attending the Indiana University School of Medicine, Dr. Mick completed his Cardiovascular Disease and Interventional Fellowships at the Cleveland Clinic Foundation. Dr. Mick participated as Principal Investigator and Co-Investigator in more than 20 cardiac clinical trials. He was a leader in developing trans-radial cardiac catheterization and holds several patents for cardiac catheters. Dr. Mick has performed over 15,000 diagnostic procedures in his 22 years of practice.

As the Director of Nursing managing a medical team which now numbers 10, Gretchen Dezelick oversees all of the clinical operations and maintains the superior cleanliness and safety standards that help make Okyanos a center of excellence. With more than 25 years of nursing experience progressing from bedside nursing to administrative and management positions in a variety of healthcare settings, Gretchen was a Certified Critical Care Nurse (CCRN) for more than 20 years and has been a Certified Peri-Operative Nurse (CNOR) for more than three years as well as being a Licensed Health Care Risk Manager (LHCRM).

Okyanos is also very proud to include several Bahamian medical staff such as Anesthesiologist Dr. Vincent Burton, Fellow of the Royal College of Anaesthetists, UK (FRCA), a Certified Critical Care Nurse, cardiology tech, sonographer, surgical scrub tech and a facilities tech, to deliver well-rounded expert patient care. The team also includes a Certified Cardiovascular Nurse, a BSN RN and a cardiovascular tech, providing more than 88 years of combined experience.

Okyanos follows the treatment guidelines laid out in clinical trials such as PRECISE and others which have demonstrated positive results from adult stem cell therapy. Okyanos cell therapy is performed in their newly constructed surgery center built to U.S. surgical standards and which also includes a state-of-the-art Phillips cath lab.

Adult stem cell therapy has emerged as a new treatment alternative for those who are restricted in activities they can no longer do but are determined to live a more normal life. Okyanos cell therapy uses a unique blend of adult stem cells derived from a patients own fat tissue, thereby helping the bodys own natural biology to heal itself.

Just 50 miles from US shore, Okyanos cell therapy is available to patients with severe heart disease including coronary artery disease (CAD) and congestive heart failure (CHF) as well as patients with autoimmune diseases, tissue ischemia, neurological and orthopedic conditions.

See the article here:
Okyanos Expands World-Class Cell Therapy Medical Team

Posted in Stem Cell Therapy | Comments Off on Okyanos Expands World-Class Cell Therapy Medical Team

Stem cells born out of indecision

Posted: December 18, 2014 at 11:49 pm

PUBLIC RELEASE DATE:

18-Dec-2014

Contact: Joshua Brickman joshua.brickman@sund.ku.dk 45-51-68-04-38 University of Copenhagen - The Faculty of Health and Medical Sciences

This latest research by Joshua Brickman and his research team from Danish Stem Cell Center (Danstem) at the University of Copenhagen specifically found that inhibiting or blocking stem cells ability to make a specific decision, leads to better cell growth and could lead to defined ways to differentiate stem cells.

This research is the first comprehensive analysis of a pathway important for stem and cancer cell decisions known as Erk. As a result this work could contain clues to cancer treatment as well as helping to establish a platform to make stem cell treatments for gut related disorders like the pancreas or the liver.

The research results have just been published in Cell Reports.

Blocking choices

"If you block all the choices they can make, they stay in the stem cell state. If you only allow them one door to exit from the stem cell state, you should be able to make particular cell types more efficiently. So if you only leave one door open then it's the path of least resistance and when you give them a push they really go," says Professor Joshua Brickman.

As embryonic stem cells can become any cell type in the body, they have to make choices. Based on this research, it appears that blocking these choices is the key to making them grow as stem cells. In other words, if these choices are removed the cells simply reproduce more stem cells.

Embryonic stem cells

See more here:
Stem cells born out of indecision

Posted in Stem Cells | Comments Off on Stem cells born out of indecision

Still no stem cells via easy 'STAP' path

Posted: December 18, 2014 at 11:49 pm

The Asahi Shimbun via Getty Images

In a January 2014 press conference in Kobe, Japan, Haruko Obokata points to microscope pictures of mouse cells engineered to glow green to indicate a stem-cell status.

Haruko Obokata, the Japanese stem-cell biologist whose papers caused a sensation earlier this year before being retracted, has not succeeded in an attempt to replicate the controversial experiments, the Japanese media has reported.

The original papers, which Obokata co-authored and published in Nature in January1, 2, claimed to provide a way of producing 'pluripotent' stem cells cells with the ability to develop into almost any cell type in the body by a much easier route than used by earlier methods, including a technology that won the 2012 physiology Nobel prize. Obokata's technique involved inducing pluripotency in mouse adult cells by subjecting them to stress, such as physical pressure or exposure to acid. The technique was called stimulus-triggered acquisition of pluripotency, or STAP.

The papers garnered much excitement, but immediately came underattack by social mediathat noted apparently manipulated images. Investigations by the RIKEN Center for Developmental Biology in Kobe, where Obokata works, found that she had committed scientific misconduct, and thepapers were retracted.

Obokata, however, stood by her results, and the RIKEN Center gave her until the end of November to prove that she could reproduce them.

In the experiments, the cells were engineered to glow with green fluorescence when they expressed genes related to pluripotency. Obokata's repeat experiments reportedly produced such green glowing cells. But this is only a preliminary test and involves just a few such cells. More rigorous tests, including the introduction of the cells to a mouse embryo to see whether they could contribute to various tissues in a developing animal, did not produce the hoped-for results.

An official announcement will be made at a press conference on 19 December.

More:
Still no stem cells via easy 'STAP' path

Posted in Stem Cells | Comments Off on Still no stem cells via easy 'STAP' path

European court clears way for stem-cell patents

Posted: December 18, 2014 at 11:49 pm

Miodrag Stojkovic/SPL

Some types of human embryonic stem cells can now be patented in Europe.

Europes highest court has ruled that human embryonic stem cells made from unfertilized eggs can be patented on the basis that they lack the potential to turn into a human being.

The cells in question are created through a process called parthenogenesis, after the Greek words for virgin and birth. In some animals, parthenogenesis is a means of asexual reproduction but human cells created in this way are not capable of properly developing.

The ruling, issued on 18 December by the European Court of Justice, backtracks on the court's more general, 2011 ban on obtaining patents for human embryonic stem cells (ESCs).

The ban had come in response to a patent sought by stem-cell scientist Oliver Brstle of the University of Bonn, Germany, for neurons made from ESCs. As well as banning patents that involve the destruction of cells capable of forming human embryos, the court specifically forbade patents on ESCs made from 'parthenote' eggs, stating that they are capable of commencing the process of development which leads to a human being.

But many scientists denounced the decision, arguing that it would slow the development of cell-based therapies. We have known for a very long time that parthenogenetic (or parthenote) embryos are not capable of developing very far after implantation, says Robin Lovell-Badge, a stem-cell scientist at the National Institute for Medical Research in London.

International Stem Cell Corporation, a biotechnology company in Carlsbad, California, challenged the judgement after a UK application it made for two patents was rejected. The patents covered methods to generate corneal tissue from ESCs that had been made from egg cells, or ova, via parthenogenesis.

In its 18 December ruling, the court said: "The mere fact that a parthenogenetically-activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo." It is now up to UK courts to decide whether the cells generated by International Stem Cell Corporation qualify for patent protection.

Julian Hitchcock, a biotechnology lawyer at Lawford Davies Denoon in London, says that the courts decision raises questions about the advice that underpinned the 2011 findings. The ruling could spur further challenges to the patent ban, he adds.

See original here:
European court clears way for stem-cell patents

Posted in Stem Cells | Comments Off on European court clears way for stem-cell patents

EU court clears stem cell patenting

Posted: December 18, 2014 at 11:49 pm

LUXEMBOURG: A human egg used to produce stem cells but unable to develop into a viable embryo can be patented, the European Court of Justice ruled on Thursday (Dec 18).

In a decision of huge interest for biotechnology companies investing in stem-cell research, the EU's top court decided such eggs did not meet the definition of what constituted a human embryo. "Accordingly, uses of such an organism for industrial or commercial purposes may, as a rule, be patented," the court said in a statement summary of the decision.

In July, Advocate General Pedro Cruz Villalon recommended to the European Court of Justice that stem cells do not come under EU rules which deny patents on eggs which could develop into a human embryo. The ECJ is Europe's top court on questions of EU law and mostly follows such recommendations.

The case was brought by International Stem Cell Corporation against the UK Intellectual Property Office for refusing to grant it two patents. The British authorities had argued that since the eggs involved were active and developing, even if not fertilised by male sperm, then European Union law meant the company could not secure a patent on them.

ISC contested the ruling, saying the eggs, activated by a chemical process known as parthenogenesis, could not develop into human beings as they lacked the full parental DNA required.

Human embryonic stem cells originally came from normally fertilised eggs but this caused serious ethical misgivings since the embryos were subsequently destroyed as the stem cells were collected. As a result, scientists welcomed the development of parthenogenesis as it met at least some of these concerns, allowing them a clearer conscience in one of the pioneer fields of healthcare research.

Cruz Villalon also recognised, however, that recent research had pointed to the possibility that such eggs might in the future be so modified that they could in effect be considered human embryos. In that case, European Union member states would still have the right under existing law to deny patents on ethical and moral grounds, he said.

See the article here:
EU court clears stem cell patenting

Posted in Stem Cells | Comments Off on EU court clears stem cell patenting

Neil Segil uses stem cells to seek treatments for hearing loss – Video

Posted: December 18, 2014 at 8:40 am


Neil Segil uses stem cells to seek treatments for hearing loss
USC Stem Cell researcher Neil Segil seeks ways to treat hearing loss and balance disorders through the regeneration of inner ear cells. His lab explores why lost sensory cells don #39;t naturally...

By: USC

Excerpt from:
Neil Segil uses stem cells to seek treatments for hearing loss - Video

Posted in Stem Cell Videos | Comments Off on Neil Segil uses stem cells to seek treatments for hearing loss – Video

Page 1,904«..1020..1,9031,9041,9051,906..1,9101,920..»